Category Archives: oud

Apple iPhone Socked As Smartphone Market Hits The Brakes

Smartphone shipment growth is projected to drop into the single digits worldwide this year, led by China’s transition from developing to mature market, research firm IDC said Wednesday. Apple ’s ( AAPL ) iPhone is likely to be much harder-hit than handsets using Alphabet ’s ( GOOGL ) Android operating system, IDC said. It sees iPhone shipments declining 0.1% in 2016, while Android phone shipments rise 7.6%. IDC predicts that total smartphone shipments will rise 5.7% to 1.5 billion units in 2016. Last year, smartphone shipments rose 10.4% to 1.44 billion units. IDC forecasts that Android smartphones will make up 82.6% of shipments in 2016, with 1.25 billion units. It projects Android smartphone shipments will grow at a five-year compound annual rate of 6.9% and reach 84.6% market share in 2020. Meanwhile, Apple’s iPhone will account for 15.2% of smartphone shipments in 2016, with 231 million units, IDC said. The research firm estimates that iPhone shipments will grow at a five-year compound annual rate of 3% and slip to 14% market share by 2020. Overall smartphone shipments are seen hitting 1.92 billion units in 2020, with volumes continuing to shift to lower-cost handsets. The average selling price for a smartphone is forecast to drop to $237 in 2020 from $295 in 2015, IDC said. Mature markets like the U.S., Western Europe and China all hit single-digit growth in smartphones in 2015, while high-growth emerging markets such as India, Indonesia, the Middle East and Africa, and other pockets of Southeast Asia all remained healthy. “The mature market slowdown has some grave consequences for Apple, as well as the high-end Android space, as these were the markets that absorbed the majority of the premium handsets that shipped over the past five years,” IDC analyst Ryan Reith said in a statement. “I believe Apple’s move into the trade-in business with its ‘Trade Up with Installments’ program is aimed at further increasing churn in some of its most lucrative markets despite the high penetration rates. By entering this space, Apple can more tightly control the trade-in offerings, as well as monitor the demand for where these perfectly functioning one-year old iPhones end up. The latter is just as important as the trade-in location, as it will give Apple a strong pulse on areas of high demand but perhaps less disposable income.” Large-screen smartphones, or phablets, continue to be a growth segment of the market. Phablets accounted for 20% of smartphone volumes in 2015 and are forecast to reach 32% of shipment volumes in 2020, IDC said. Apple’s iPhone sales to end users fell for the first time ever in the fourth quarter, research firm Gartner reported last month . Apple has projected that its iPhone sales into the sales channel will drop on a year-over-year basis for the first time this quarter. Image provided by Shutterstock . RELATED:  Apple Working On Dual-Camera iPhone 7 Plus Smartphone: Analyst .

BioMarin Stock Up As Drug Slows Progress Of Deadly Rare Disease

Shares of rare-disease specialist BioMarin Pharmaceutical ( BMRN ) rose Thursday after the company reported late Wednesday that its drug for Batten disease was on track for approval after a successful trial. BioMarin presented data from its pivotal study of 24 children taking its drug cerliponase alfa for the rare genetic condition, which causes most of its sufferers to lose the ability to walk and talk by the age of six and to die before they reach puberty. Though at least 20 genes have been associated with Batten disease, cerliponase alfa targets patients with a CLN2 mutation, who BioMarin estimates number 1,200 to 1,600 in its commercial territories. BioMarin said patients taking the drug showed 80% less than the expected rate of decline in function for the untreated population, and that the treatment was generally safe and well-tolerated. MRI measurement also showed a slower rate of brain deterioration. The company said it plans to submit the drug for approval with the FDA and the European Medicines Agency around midyear. Cerliponase alfa has already been designated an orphan drug, which means it will be protected from competition in the near term if it is approved. “Whether FDA will approve this is not clear, but stabilization is a major treatment effect in these very sick children, and they’ve had ‘very fulsome dialogue about requirements to support registration’ with agencies,” wrote RBC Capital Markets analyst Michael Yee in a research note. “They haven’t communicated specifically what the numerical benchmark is to get approved, but agencies are aware of the natural-history evidence.” Yee estimates peak annual sales of at least $250 million for the drug, while Evercore ISI analyst Mark Schoenebaum reckons the opportunity at double that number. BioMarin stock was up nearly 2% in late-morning trading on the stock market today , near 89. The stock has been recovering since hitting an 18-month low on Feb. 10, as it suffered both from the market sell-off and the FDA’s rejection of its muscular dystrophy drug Kyndrisa in January. Other MD drug candidates haven’t been faring much better: The FDA put off making a decision on Sarepta Therapeutics ‘ ( SRPT ) eteplirsen until May after issuing a scathing assessment of the drug in its briefing documents, while PTC Therapeutics ( PTCT ) said Monday that the FDA had refused to receive its application for ataluren, despite its having already been approved in Europe.